膠原病性血液疾患の世界市場 (製品別、適応症別、最終用途別)：将来予測 (2025～2030年)

膠原病性血液疾患市場は、2023年に298億3,000万米ドルと評価され、2024年には322億1,000万米ドルに達すると予測され、2030年には535億1,000万米ドルまで8.70%のCAGRで成長すると予測されています。

膠原病性血液疾患（CVD）は、身体の免疫系が結合組織の不可欠な構成要素であるコラーゲンを誤って攻撃する自己免疫疾患群です。CVD治療薬の必要性と応用は、ループス、強皮症、関節リウマチなど、患者が炎症、疼痛、組織損傷に苦しむ疾患への対処にあります。これらの治療薬は患者のQOLを向上させるだけでなく、慢性症状の長期管理に伴う医療コストの削減にも不可欠です。最終用途の範囲は病院、診療所、専門医療センターに及び、そこでは処方薬または先進生物製剤による治療が行われます。市場成長の主な要因は、治療手法の技術的進歩、自己免疫疾患の有病率の増加、早期診断と早期介入に対する意識の高まりです。個別化医療と標的療法の開発には主な機会が存在し、有効性の向上と副作用の軽減が期待できます。企業は、患者データ分析のためのAI主導型アナリティクスの活用と、より良いアウトリーチと患者モニタリングのための遠隔医療サービスの統合に注力すべきです。

しかし、同市場は、高額な治療費、厳しい規制当局の承認、免疫抑制剤の長期使用に伴う潜在的な副作用といった大きな課題に直面しています。さらに、自己免疫疾患のメカニズムが複雑であるため、医薬品開発や研究がしばしば複雑化します。市場拡大には、こうした側面への対処が不可欠となる可能性があります。バイオマーカー同定における革新と遺伝子研究の進歩は、特に個別化医療と精密医療におけるブレークスルーのための肥沃な土壌を提供します。製薬会社と研究機関の共同研究は、新規治療薬の開発に先鞭をつける可能性があり、政府および民間の資金提供イニシアティブによってさらに推進されます。CVD治療薬市場は、急速な技術革新の一方で、患者の経済的な負担とアクセスにおけるハードルという特徴を持っており、進歩的な可能性と内在する課題という二面性を示しています。

市場力学：急速に進化する膠原病性血液疾患市場の主要市場インサイトを公開

膠原病性血液疾患市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 膠原病性血液疾患に対する認識と理解の高まり
  • 自己免疫疾患の世界の増加
  • 医療インフラの改善と医療サービスへのアクセシビリティの向上
• 市場抑制要因
  • 高度な治療や投薬に伴う高コスト
• 市場機会
  • 遺伝子治療と幹細胞治療の継続的な進歩
  • 患者管理のための遠隔医療、モバイルヘルスアプリケーション、ウェアラブルの採用
• 市場の課題
  • 政府の厳しい規制と承認プロセス

ポーターのファイブフォース：膠原病性血液疾患市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：膠原病性血液疾患市場における外部からの影響の把握

外部マクロ環境要因は、膠原病性血液疾患市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：膠原病性血液疾患市場における競合情勢の把握

膠原病性血液疾患市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：膠原病性血液疾患市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、膠原病性血液疾患市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：膠原病性血液疾患市場における成功への道筋を描く

膠原病性血液疾患市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

当レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1. 市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2. 市場の発展度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3. 市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4. 競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5. 製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1. 現在の市場規模と今後の成長予測は？

2. 最高の投資機会を提供する製品、セグメント、地域はどこか？

3. 市場を形成する主な技術動向と規制の影響とは？

4. 主要ベンダーの市場シェアと競合ポジションは？

5. ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序論

第2章 分析手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 膠原病性血液疾患に対する認識と理解の高まり
    • 自己免疫疾患の発症率が世界的に上昇
    • 医療インフラの改善と医療サービスへのアクセスの向上
  • 抑制要因
    • 高度な治療や薬剤に関連する高額な費用
  • 機会
    • 遺伝子および幹細胞治療の継続的な進歩
    • 患者管理のための遠隔医療、モバイルヘルスアプリケーション、ウェアラブルの導入
  • 課題
    • 厳格な政府規制と承認プロセス
• 市場セグメンテーション分析
  • 製品：膠原病性血液疾患における生検キットの使用増加
  • 適応症：皮膚筋炎の治療薬としての利用が増加中
  • 最終用途：さまざまな健康状態を診断するための診断センターや研究所での使用拡大
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的要因
  • 経済的要因
  • 社会的要因
  • 技術的要因
  • 法的要因
  • 環境的要因

第6章 膠原病性血液疾患市場：製品別

• 診断
  • 生検
  • 血液検査
  • 心エコー検査
  • 画像検査
  • 尿検査
• 治療
  • 投薬療法
  • 理学療法

第7章 膠原病性血液疾患市場：適応症別

• 強直性脊椎炎
• 皮膚筋炎
• 結節性多発動脈炎
• 多発性筋炎
• 乾癬性関節炎
• 再発性多発軟骨炎
• 関節リウマチ
• 強皮症
• 全身性エリテマトーデス
• 血管炎

第8章 膠原病性血液疾患市場：最終用途別

• 診断センター・検査室
• 病院・クリニック

第9章 南北アメリカの膠原病性血液疾患市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の膠原病性血液疾患市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの膠原病性血液疾患市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析 (2023年)
• FPNVポジショニングマトリックス (2023年)
• 競合シナリオ分析
  • クエスト・ダイアグノスティクスとサイファー・メディシンが提携し、関節リウマチ患者への精密医療へのアクセスを拡大
  • FDA、関節リウマチ、若年性関節リウマチの治療として初のトシリズマブバイオシミラーを承認
  • アメリカリウマチ学会が関節リウマチの転帰を測定するための新しいツールキットを発表
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AbbVie Inc.
• Apollo Health and Lifestyle Limited
• Augurex Life Sciences Corporation
• Bayer AG
• Beckman Coulter, Inc.
• Bio-Rad Laboratories Inc.
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb
• Eli Lilly and Company
• Exagen Inc.
• F. Hoffmann-La Roche Ltd
• Getinge AB
• Gilead Sciences, Inc.
• Illumina, Inc.
• Laboratory Corporation of America Holdings
• LeMaitre Vascular, Inc.
• Merck KGaA
• Novartis AG
• PerkinElmer, Inc.
• Pfizer Inc,
• QIAGEN GmbH
• Siemens AG
• Thermo Fisher Scientific, Inc.
• Trinity Biotech PLC

LIST OF FIGURES

• FIGURE 1. COLLAGEN VASCULAR DISEASES MARKET RESEARCH PROCESS
• FIGURE 2. COLLAGEN VASCULAR DISEASES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. COLLAGEN VASCULAR DISEASES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. COLLAGEN VASCULAR DISEASES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. COLLAGEN VASCULAR DISEASES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. COLLAGEN VASCULAR DISEASES MARKET DYNAMICS
• TABLE 7. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BLOOD TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ECHOCARDIOGRAM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY URINALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DERMATOMYOSITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY POLYARTERITIS NODOSA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY POLYMYOSITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY RELAPSING POLYCHONDRITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SCLERODERMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSTIC CENTERS & LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 49. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 50. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 51. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 52. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 53. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 57. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 58. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 64. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 70. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 72. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 73. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 74. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 76. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 77. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 78. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 79. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 80. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 81. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 82. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 83. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 84. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 85. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 87. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 88. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 89. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 90. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 92. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 93. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 94. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 95. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 97. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 98. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 99. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 100. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 102. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 103. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 104. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 105. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 107. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 108. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 109. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 110. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 112. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 113. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 114. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 115. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 117. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 118. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 119. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 120. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 122. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 123. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 124. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 125. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 127. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 128. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 129. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 130. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 134. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 135. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 136. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 138. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 139. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 140. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 141. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 143. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 144. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 145. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 146. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 148. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 149. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 150. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 151. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 153. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 154. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 155. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 156. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 158. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 159. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 160. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 161. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 163. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 164. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 165. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 166. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 167. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 168. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 169. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 170. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 171. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 173. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 174. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 175. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 176. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 178. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 179. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 180. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 181. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 183. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 184. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 185. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 186. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 187. POLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 188. POLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 189. POLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 190. POLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 191. POLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 192. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 193. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 194. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 195. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 196. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 198. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 199. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 200. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 201. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 203. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 204. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 205. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 206. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 209. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 210. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 211. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 213. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 214. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 215. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 216. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 218. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 219. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 220. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 221. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 223. SWITZERLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 224. SWITZERLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 225. SWITZERLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 226. SWITZERLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 228. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 229. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 230. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 231. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 233. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 234. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 235. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 236. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 238. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 239. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 240. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 241. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 242. COLLAGEN VASCULAR DISEASES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 243. COLLAGEN VASCULAR DISEASES MARKET, FPNV POSITIONING MATRIX, 2023

The Collagen Vascular Diseases Market was valued at USD 29.83 billion in 2023, expected to reach USD 32.21 billion in 2024, and is projected to grow at a CAGR of 8.70%, to USD 53.51 billion by 2030.

Collagen Vascular Diseases (CVDs) represent a group of autoimmune disorders where the body's immune system mistakenly attacks its collagen, an integral component of connective tissues. The necessity and application of CVD therapeutics lie in addressing diseases such as lupus, scleroderma, and rheumatoid arthritis, where patients suffer from inflammation, pain, and tissue damage. These therapies are vital not only for improving patient quality of life but also for reducing healthcare costs associated with long-term management of chronic symptoms. The end-use scope spans hospitals, clinics, and specialized care centers where treatments are administered either through prescription medication or advanced biologics. Market growth is chiefly influenced by technological advancements in treatment methodologies, increasing prevalence of autoimmune conditions, and rising awareness about early diagnosis and intervention. Key opportunities exist in the development of personalized medicine and targeted therapies, promising enhanced efficacy and reduced side effects. Companies should focus on leveraging AI-driven analytics for patient data analysis and integrating telemedicine services for better outreach and patient monitoring.

However, the market faces significant challenges such as high treatment costs, stringent regulatory approvals, and potential side effects associated with long-term use of immunosuppressive drugs. Additionally, the complexity of autoimmune disease mechanisms often complicates drug development and research. Addressing these aspects could be critical for market expansion. Innovations in biomarker identification and advancements in genetic research offer fertile ground for breakthroughs, particularly in personalized and precision medicine. Collaborations between pharmaceutical companies and research institutions could spearhead the development of novel therapeutics, further propelled by governmental and private funding initiatives. The CVD therapeutics market is characterized by rapid technological embrace yet hurdles in patient affordability and access, indicating a dual nature of progressive potential and inherent challenges.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Collagen Vascular Diseases Market

The Collagen Vascular Diseases Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing awareness and understanding of collagen vascular diseases
  • Rising incidence of autoimmune diseases globally
  • Improved healthcare infrastructure and increased accessibility to medical services
• Market Restraints
  • High cost associated with advanced treatments and medications
• Market Opportunities
  • Ongoing advancements in gene and stem cell therapies
  • Adoption of telemedicine, mobile health applications, and wearables for patient management
• Market Challenges
  • Stringent government regulations and approval processes

Porter's Five Forces: A Strategic Tool for Navigating the Collagen Vascular Diseases Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Collagen Vascular Diseases Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Collagen Vascular Diseases Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Collagen Vascular Diseases Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Collagen Vascular Diseases Market

A detailed market share analysis in the Collagen Vascular Diseases Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Collagen Vascular Diseases Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Collagen Vascular Diseases Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Collagen Vascular Diseases Market

A strategic analysis of the Collagen Vascular Diseases Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Collagen Vascular Diseases Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Apollo Health and Lifestyle Limited, Augurex Life Sciences Corporation, Bayer AG, Beckman Coulter, Inc., Bio-Rad Laboratories Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Eli Lilly and Company, Exagen Inc., F. Hoffmann-La Roche Ltd, Getinge AB, Gilead Sciences, Inc., Illumina, Inc., Laboratory Corporation of America Holdings, LeMaitre Vascular, Inc., Merck KGaA, Novartis AG, PerkinElmer, Inc., Pfizer Inc,, QIAGEN GmbH, Siemens AG, Thermo Fisher Scientific, Inc., and Trinity Biotech PLC.

Market Segmentation & Coverage

This research report categorizes the Collagen Vascular Diseases Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Diagnosis and Treatments. The Diagnosis is further studied across Biopsy, Blood Test, Echocardiogram, Imaging Tests, and Urinalysis. The Treatments is further studied across Medications and Physical Therapy.
• Based on Indication, market is studied across Ankylosing Spondylitis, Dermatomyositis, Polyarteritis Nodosa, Polymyositis, Psoriatic Arthritis, Relapsing Polychondritis, Rheumatoid Arthritis, Scleroderma, Systemic Lupus Erythematosus, and Vasculitis.
• Based on End-Use, market is studied across Diagnostic Centers & Laboratories and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing awareness and understanding of collagen vascular diseases
    • 5.1.1.2. Rising incidence of autoimmune diseases globally
    • 5.1.1.3. Improved healthcare infrastructure and increased accessibility to medical services
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with advanced treatments and medications
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing advancements in gene and stem cell therapies
    • 5.1.3.2. Adoption of telemedicine, mobile health applications, and wearables for patient management
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent government regulations and approval processes
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Increasing usage of biopsy kits in collagen vascular diseases
  • 5.2.2. Indication: Increasing utilization for indicating dermatomyositis
  • 5.2.3. End-Use: Expanding usage among diagnostic centers & laboratories to diagnose various health conditions
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Collagen Vascular Diseases Market, by Product

• 6.1. Introduction
• 6.2. Diagnosis
  • 6.2.1. Biopsy
  • 6.2.2. Blood Test
  • 6.2.3. Echocardiogram
  • 6.2.4. Imaging Tests
  • 6.2.5. Urinalysis
• 6.3. Treatments
  • 6.3.1. Medications
  • 6.3.2. Physical Therapy

7. Collagen Vascular Diseases Market, by Indication

• 7.1. Introduction
• 7.2. Ankylosing Spondylitis
• 7.3. Dermatomyositis
• 7.4. Polyarteritis Nodosa
• 7.5. Polymyositis
• 7.6. Psoriatic Arthritis
• 7.7. Relapsing Polychondritis
• 7.8. Rheumatoid Arthritis
• 7.9. Scleroderma
• 7.10. Systemic Lupus Erythematosus
• 7.11. Vasculitis

8. Collagen Vascular Diseases Market, by End-Use

• 8.1. Introduction
• 8.2. Diagnostic Centers & Laboratories
• 8.3. Hospitals & Clinics

9. Americas Collagen Vascular Diseases Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Collagen Vascular Diseases Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Collagen Vascular Diseases Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis
  • 12.3.2. FDA Approves First Tocilizumab Biosimilar For Treatment Of Rheumatoid Arthritis, JIA
  • 12.3.3. American College of Rheumatology Launches New Toolkit Aimed at Measuring Rheumatoid Arthritis Outcomes
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AbbVie Inc.
• 3. Apollo Health and Lifestyle Limited
• 4. Augurex Life Sciences Corporation
• 5. Bayer AG
• 6. Beckman Coulter, Inc.
• 7. Bio-Rad Laboratories Inc.
• 8. Boehringer Ingelheim International GmbH
• 9. Bristol-Myers Squibb
• 10. Eli Lilly and Company
• 11. Exagen Inc.
• 12. F. Hoffmann-La Roche Ltd
• 13. Getinge AB
• 14. Gilead Sciences, Inc.
• 15. Illumina, Inc.
• 16. Laboratory Corporation of America Holdings
• 17. LeMaitre Vascular, Inc.
• 18. Merck KGaA
• 19. Novartis AG
• 20. PerkinElmer, Inc.
• 21. Pfizer Inc,
• 22. QIAGEN GmbH
• 23. Siemens AG
• 24. Thermo Fisher Scientific, Inc.
• 25. Trinity Biotech PLC